Improving engineered T-cell therapy for pancreatic cancer
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma
Engineered T cells that target the protein mesothelin are being developed to shrink tumors and change the tumor environment for people with pancreatic cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11211991 on NIH RePORTER |
What this research studies
Researchers are creating T cells engineered to carry a receptor that recognizes mesothelin, a protein commonly found on pancreatic tumor cells. They are testing these T cells in aggressive animal models that mimic human pancreatic ductal adenocarcinoma to see how well the cells kill cancer and break down the surrounding fibrous stroma. The team measures tumor responses, how the engineered T cells accumulate in tumors, and changes in immune cells in the tumor microenvironment. Findings are intended to guide future clinical testing of this approach in patients.
Who could benefit from this research
Good fit: Ideal candidates would be people with advanced pancreatic ductal adenocarcinoma whose tumors express mesothelin and who are medically eligible for cell-based immunotherapy trials.
Not a fit: Patients whose tumors lack mesothelin, who are too frail for cell therapy, or who have active autoimmune disease may not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could make immunotherapy work better in pancreatic cancer, reduce tumor-supporting stroma, and potentially extend survival.
How similar studies have performed: T-cell therapies targeting tumor antigens have succeeded in some cancers and mesothelin-targeting approaches have shown promise, but pancreatic cancer remains difficult and this engineered strategy is relatively new with encouraging preclinical results.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Stromnes, Ingunn Margarete — University of Minnesota
- Study coordinator: Stromnes, Ingunn Margarete
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.